ROCHE HOLDING LTD

Insider Reports History

Location
Basel, Switzerland
Signature
ROCHE FINANCE LTD, By: /s/ Peter Trybus, Authorized Signatory
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by ROCHE HOLDING LTD:

Company Role Class Num Shares Value Price $ Report Date Ownership
Entrada Therapeutics, Inc. 10%+ Owner Common Stock 2,813,525 $44,988,265 $15.99 02 Nov 2021 Indirect
Jasper Therapeutics, Inc. 10%+ Owner Voting Common Stock 4,549,606 $2,950,874 $0.6486 25 Jan 2023 Indirect
Aligos Therapeutics, Inc. 10%+ Owner Common Stock, par value $0.0001 per share 11,025,941 25 Oct 2023 Indirect
Entrada Therapeutics, Inc. 10%+ Owner Series A Preferred Stock 0 02 Nov 2021 Indirect
Entrada Therapeutics, Inc. 10%+ Owner Series B Preferred Stock 0 02 Nov 2021 Indirect

Insider Reports Filed by ROCHE HOLDING LTD

Symbol Company Period Transactions Value $ Form Type Role Filing Time
ALGS Aligos Therapeutics, Inc. 25 Oct 2023 0 $0 3 10%+ Owner 07 Nov 2023, 17:14
JSPR Jasper Therapeutics, Inc. 25 Jan 2023 1 -$141,750 4 10%+ Owner 26 Jan 2023, 16:49
TRDA Entrada Therapeutics, Inc. 02 Nov 2021 4 $0 4 10%+ Owner 04 Nov 2021, 21:45
TRDA Entrada Therapeutics, Inc. 28 Oct 2021 0 $0 3 10%+ Owner 28 Oct 2021, 21:04
JSPR Jasper Therapeutics, Inc. 24 Sep 2021 0 $0 3 10%+ Owner 04 Oct 2021, 09:10